2000: October: Dementia-Alzheimer’s Research Papers

2000: October: Dementia-Alzheimer’s Research Papers     

           

Lambert JC, Mann D, Goumidi L, Harris J, Pasquier F, Frigard B, Cottel D, Lendon C, Iwatsubo T, Amouyel P, Chartier-Harlin MC. A FE65 polymorphism associated with risk of developing sporadic late-onset alzheimer's disease but not with Abeta loading in brains. Neurosci Lett. 2000 Oct 20;293(1):29-32. ,

Yang LB, Li R, Meri S, Rogers J, Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci. 2000 Oct 15;20(20):7505-9. ,

 

López Salon M, Morelli L, Castaño EM, Soto EF, Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res. 2000 Oct 15;62(2):302-10.

Lovell MA, Xie C, Markesbery WR. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic Biol Med. 2000 Oct 15;29(8):714-20.

Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ. Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J. 2000 Oct 15;351 Pt 2:509-16.

Nakajima M, Shimizu T, Shirasawa T. Notch-1 activation by familial Alzheimer's disease (FAD)-linked mutant forms of presenilin-1. J Neurosci Res. 2000 Oct 15;62(2):311-7.

Lewis PA, Perez-Tur J, Golde TE, Hardy J. The presenilin 1 C92S mutation increases abeta 42 production. Biochem Biophys Res Commun. 2000 Oct 14;277(1):261-3. ,

Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Tienari P, Niinistö L, Kontula K, Hardy J, Haltia M, Pérez-Tur J. Cardiovascular risk factors and Alzheimer's disease: a genetic association study in a population aged 85 or over. Neurosci Lett. 2000 Oct 13;292(3):195-8. , ,

Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Okamoto K, Shoji M. Impaired neurotransmitter systems by Abeta amyloidosis in APPsw transgenic mice overexpressing amyloid beta protein precursor. Neurosci Lett. 2000 Oct 13;292(3):155-8.

Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000 Oct 12;407(6805):802-9.

Voelker R. The world in medicine: recessive alzheimer gene? JAMA. 2000 Oct 11;284(14):1777.

Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9.

  

Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 2000 Oct 6;290(5489):150-3.

 

Warr O, Mort D, Attwell D. Bilirubin does not modulate ionotropic glutamate receptors or glutamate transporters. Brain Res. 2000 Oct 6;879(1-2):13-6.

Mayer P, Brunel P, Chaplain C, Piedecoq C, Calmel F, Schambel P, Chopin P, Wurch T, Pauwels PJ, Marien M, Vidaluc JL, Imbert T. New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity. J Med Chem. 2000 Oct 5;43(20):3653-64.

Hallam DM, Capps NL, Travelstead AL, Brewer GJ, Maroun LE. Evidence for an interferon-related inflammatory reaction in the trisomy 16 mouse brain leading to caspase-1-mediated neuronal apoptosis. J Neuroimmunol. 2000 Oct 2;110(1-2):66-75.

Kow YW, Dare A. Detection of abasic sites and oxidative DNA base damage using an ELISA-like assay. Methods. 2000 Oct;22(2):164-9.

Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van den Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol. 2000 Oct 1;157(4):1283-98.

Wang H, Lai S, Sun J. [Ethological examination of Alzheimer's disease model rats treated with bushen yizhi decoction] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Oct;20(10):771-3.

Dolzhanskaya N, Conti J, Merz G, Denman RB. In vivo ribozyme targeting of betaAPP+ mRNAs. Mol Cell Biol Res Commun. 2000 Oct;4(4):239-47.

Devi G, Silver J. Approaches to memory loss in neuropsychiatric disorders. Semin Clin Neuropsychiatry. 2000 Oct;5(4):259-65.

Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol. 2000 Oct;22(8):609-13.

Herz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci. 2000 Oct;1(1):51-8.

Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther. 2000 Oct;2(5):540-54.

Tong X, Zeng X, Zhou HM. Effects of zinc on creatine kinase: activity changes, conformational changes, and aggregation. J Protein Chem. 2000 Oct;19(7):553-62.

Mori E. [Dementia with Lewy bodies] Nippon Ronen Igakkai Zasshi. 2000 Oct;37(10):772-6.

Hull M, Pasinetti GM, Aisen PS. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):228-30.

Sramek JJ, Cutler NR. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):216-27.

Villa AE, Tetko IV, Dutoit P, Vantini G. Non-linear cortico-cortical interactions modulated by cholinergic afferences from the rat basal forebrain. Biosystems. 2000 Oct-Dec;58(1-3):219-28.

Ikeda E, Shiba K, Mori H, Ichikawa A, Sumiya H, Kuji I, Tonami N. Reduction of vesicular acetylcholine transporter in beta-amyloid protein-infused rats with memory impairment. Nucl Med Commun. 2000 Oct;21(10):933-7.

Yokel RA. The toxicology of aluminum in the brain: a review. Neurotoxicology. 2000 Oct;21(5):813-28.

Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, Brookes AJ. apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum Genet. 2000 Oct;107(4):391-6. ,

Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn J Pharmacol. 2000 Oct 1;84(2):101-12.

Mathews PM, Cataldo AM, Kao BH, Rudnicki AG, Qin X, Yang JL, Jiang Y, Picciano M, Hulette C, Lippa CF, Bird TD, Nochlin D, Walter J, Haass C, Lévesque L, Fraser PE, Andreadis A, Nixon RA. Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease. Mol Med. 2000 Oct;6(10):878-91.

Pastorino L, Colciaghi F, Marcon G, Borroni B, Cottini E, Cattabeni F, Padovani A, Di Luca M. Presenilin 2 mutation does not influence expression and concentration of APP forms in human platelets. Mol Med. 2000 Oct;6(10):816-24.

Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000 Oct;97(21):11455-9. Abstract

Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res. 2000 Oct;25(9-10):1357-64.

Roks G, van Harskamp F, de Koning I, Cruts M, de Jonghe C, Kumar-Singh S, Tibben A, Tanghe H, Niermeijer MF, Hofman A, van Swieten JC, van Broeckhoven C, van Duijn CM. Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain. 2000 Oct;123 ( Pt 10):2130-40.

Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000 Oct;59(10):880-8.

Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000 Oct;57(10):968-76.

  

Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengârd JH, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet. 2000 Oct;67(4):881-900.

Hatanaka Y, Kamino K, Fukuo K, Mitsuda N, Nishiwaki-Ueda Y, Sato N, Satoh T, Yamamoto H, Yoneda H, Imagawa M, Miki T, Ohta S, Ogihara T. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin Genet. 2000 Oct 1;58(4):319-23. ,

Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000 Oct 1;20(10):2255-60.

Mattila KM, Rinne JO, Röyttä M, Laippala P, Pietilä T, Kalimo H, Koivula T, Frey H, Lehtimäki T. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Genet. 2000 Oct;37(10):766-70. ,

Thatte U. Phenserine (Axonyx/NIH). IDrugs. 2000 Oct;3(10):1222-8.

Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol. 2000 Oct;131(4):711-20. ,

Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci. 2000 Oct 1;20(19):7345-52.

Devi G, Fotiou A, Jyrinji D, Tycko B, DeArmand S, Rogaeva E, Song YQ, Medieros H, Liang Y, Orlacchio A, Williamson J, St George-Hyslop P, Mayeux R. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch Neurol. 2000 Oct 1;57(10):1454-7. ,

Weller I. The relation between hip fracture and alzheimer's disease in the canadian national population health survey health institutions data, 1994-1995. A cross-sectional study. Ann Epidemiol. 2000 Oct 1;10(7):461.

Bruce-Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola S, Mattson MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology. 2000 Oct;141(10):3646-56.

McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology. 2000 Oct;217(1):58-68.

Dierks T, Jelic V, Pascual-Marqui RD, Wahlund L, Julin P, Linden DE, Maurer K, Winblad B, Nordberg A. Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol. 2000 Oct;111(10):1817-24.

Tyas SL, Pederson LL, Koval JJ. Is smoking associated with the risk of developing Alzheimer's disease? Results from three Canadian data sets. Ann Epidemiol. 2000 Oct;10(7):409-16.

 

Rotilio G, Carrì MT, Rossi L, Ciriolo MR. Copper-dependent oxidative stress and neurodegeneration. IUBMB Life. 2000 Oct-Nov;50(4-5):309-14.

Yoshikawa K. [Molecular mechanisms of differentiation and death of human neurons: with special reference to necdin and APP] Nihon Shinkei Seishin Yakurigaku Zasshi. 2000 Oct;20(4):155-9.

Higuchi S, Ohta S, Matsushita S, Matsui T, Yuzuriha T, Urakami K, Arai H. NOS3 polymorphism not associated with Alzheimer's disease in Japanese. Ann Neurol. 2000 Oct;48(4):685. ,

  

Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 2000 Oct;48(4):567-79.

    

Levey AI. Immunization for Alzheimer's disease: a shot in the arm or a whiff? Ann Neurol. 2000 Oct;48(4):553-5.

 

Weiss JH, Sensi SL, Koh JY. Zn(2+): a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci. 2000 Oct;21(10):395-401.

Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry. 2000 Oct;15(10):911-6.

Cameron I, Curran S, Newton P, Petty D, Wattis J. Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice. Int J Geriatr Psychiatry. 2000 Oct;15(10):887-91.

  

Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct;57(10):1439-43.

    

Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs. 2000 Oct;9(10):2393-402.

Korczyn AD. Muscarinic M(1) agonists in the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2000 Oct;9(10):2259-67.

MacKnight C. World Alzheimer Congress 2000. Clin Invest Med. 2000 Oct;23(5):339-41.

Schindler RJ, Cucio CP. Late-life dementia. Review of the APA guidelines for patient management. Geriatrics. 2000 Oct;55(10):55-60; quiz 62.

Della Sala S, Kinnear P, Spinnler H, Stangalino C. Color-to-Figure Matching in Alzheimer's Disease. Arch Clin Neuropsychol. 2000 Oct;15(7):571-85.

Blobel CP. Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol. 2000 Oct;12(5):606-12.

Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (Berl). 2000 Oct 1;100(4):395-402.

Pestell S, Shanks MF, Warrington J, Venneri A. Quality of spelling breakdown in Alzheimer's disease is independent of disease progression. J Clin Exp Neuropsychol. 2000 Oct;22(5):599-612.

Meguro K, Yamaguchi S, Shimada M, Itoh M, Yamadori A. Striatal dopaminergic transmission and neocortical glucose utilization in Alzheimer's disease: a triple-tracer positron emission tomography study. Arch Gerontol Geriatr. 2000 Oct 1;31(2):147-158.

Tajima K, Nanri M. [A pharmacological profile of piracetam (Myocalm), a drug for myoclonus] Nippon Yakurigaku Zasshi. 2000 Oct;116(4):209-14.

Hauw JJ, Escourolle F, Colle MA, Duyckaerts C. [Neuropathology of Alzheimer's disease] Ann Pathol. 2000 Oct;20(5):448-57.

Lopez MF, Kristal BS, Chernokalskaya E, Lazarev A, Shestopalov AI, Bogdanova A, Robinson M. High-throughput profiling of the mitochondrial proteome using affinity fractionation and automation. Electrophoresis. 2000 Oct;21(16):3427-40.

Bennett DA. Part I. Epidemiology and public health impact of Alzheimer's disease. Dis Mon. 2000 Oct;46(10):657-65.

Bennett DA. Alzheimer's disease--introduction Dis Mon. 2000 Oct;46(10):653-6.

Heinsen H, Arzberger T, Schmitz C. Celloidin mounting (embedding without infiltration) - a new, simple and reliable method for producing serial sections of high thickness through complete human brains and its application to stereological and immunohistochemical investigations. J Chem Neuroanat. 2000 Oct;20(1):49-59.

Nagy ZS, Smith MZ, Esiri MM, Barnetson L, Smith AD. Hyperhomocysteinaemia in Alzheimer's disease and expression of cell cycle markers in the brain. J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):565-6.

Vanderklish PW, Bahr BA. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol. 2000 Oct;81(5):323-39.